What is your approach to the use of denosumab in patients with metastatic breast cancer with bony involvement?
2
1 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
I do not extrapolate the results of OPTIMIZE-2 and CALGB 70604 to denosumab. It is a different drug and until appropriate studies are performed, there is no reason to change its dose or schedule.